Company intelligence / Profile preview
Madrigal Pharmaceuticals
- Ownership
- Public · MDGL
- Employees
- ~528
- Development stage
- Phase 3
Overview
Madrigal Pharmaceuticals developed resmetirom (brand name Rezdiffra), a first-in-class oral small-molecule thyroid hormone receptor beta agonist. In March 2024, it became the first FDA-approved treatment for MASH with moderate to advanced liver fibrosis. The pivotal Phase 3 MAESTRO-NASH trial demonstrated significant efficacy and safety results published in The New England Journal of Medicine. The company has since launched Rezdiffra commercially in the US.
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $12.6B
- Total revenue
- $364.3M
- Enterprise value
- $12.1B
Beyond the preview
Go deeper on Madrigal Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Madrigal Pharmaceuticals.